Ikena Oncology Inc at Stifel Healthcare Conference (Virtual) Transcript
All right. Good morning. I'm Stephen Willey, one of the senior biotech analysts here at Stifel and glad to have with us this morning presenting Ikena Oncology. We have Mark Manfredi, who is the CEO; we have Doug Carlson, who is the CFO; and we have Sergio Santillana, who is the Chief Medical Officer. Mark is going to walk us through a presentation, give us an overview of the company. We should have some time at the end for Q&A.
I'm going to hand it over to Mark, and thanks for being here this morning, Mark.
Thanks, Stephen. Thanks for the invitation to present Ikena. So I'll be making some forward-looking statements.
So we are an oncology company, clinical stage and focused in targeted agents in two areas. One is the immune signaling in the tumor microenvironment, where we're working in programs in the immunometabolism, and we'll talk about one of those programs today. And
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |